百雀羚 跨界做医美了

The article highlights Pechoin's foray into medical aesthetics and its rapid growth on Douyin, underscoring the sector's potential as a new growth driver for the beauty industry.

1. Pechoin established Guangxi Pechoin Medical Beauty Technology Co., Ltd., focusing on R&D and fully owned by Shanghai Pechoin Biomedical Co., Ltd. Both companies were founded in March 2025, signaling a strategic expansion into medical aesthetics.

2. Douyin sales data shows Pechoin's revenue reached 100-250 million yuan in February 2025, surging 123.68% month-on-month and 1692.91% year-on-year, ranking 9th among Douyin's top 20 beauty brands with the highest growth rate in the top 10, highlighting e-commerce's vast opportunities.

3. The medical aesthetics market holds significant potential, with a 17% penetration rate among China's 15-39 age group. Consumers in this segment spend 1.4 times more on skincare than non-users, shifting from one-off solutions to cyclical treatments integrated with daily routines, indicating an industry trend.

4. Other beauty players like Yatsen Global establishing Shanghai Ruikeyi E-commerce, Marubi rebranding as "Marubi Bio," and Shanghai Jahwa investing in Shanghai Langmuda Biotechnology (58% stake) confirm cross-sector moves into medical aesthetics as a widespread trend.

The article offers actionable insights for brand marketing, consumer trends, and product development to optimize strategy.

1. Marketing and channel strategy: Douyin emerges as a key growth channel, with Pechoin's case showing high sales and growth rates (123.68% MoM, 1692.91% YoY), offering a model for strengthening e-commerce and digital marketing.

2. Consumer behavior trends: Medical aesthetics' 17% penetration rate and 1.4x higher skincare spending indicate a shift toward cyclical solutions combined with daily care, requiring brands to adapt product lines.

3. Product R&D and pricing: Crossovers into medical aesthetics, like Pechoin's new company and GY's medical device collaborations, suggest opportunities for innovative products and competitive pricing to attract this demographic.

4. Market opportunities: Medical aesthetics as a growth area, evidenced by moves from Yatsen Global and Marubi, prompts brands to develop integrated skincare solutions.

The article reveals growth markets, demand shifts, and business opportunities, providing actionable takeaways for sellers.

1. Market and demand changes: Medical aesthetics' 17% penetration rate expands the skincare market, with demand shifting to cyclical regimens. Sellers can adjust product portfolios to align with treatment-plus-daily-care trends.

2. Opportunities and models: Cross-sector moves like Pechoin's new venture and Shanghai Jahwa's 58% stake in a biotech firm present partnership avenues. Sellers can explore similar investment or R&D models.

3. Risk management: Douyin's high growth (Pechoin's 123.68% MoM surge) underscores e-commerce potential but requires vigilance on demand shifts. Sellers should optimize supply chains and marketing.

4. Lessons and support: Pechoin's success highlights channel innovation; sellers can emulate its agility and seek platform collaborations for growth support.

The article provides guidance on product design, business opportunities, and digitalization for factory transformation.

1. Production and design needs: Medical aesthetics trends drive demand for cyclical-daily hybrid solutions. Factories should develop related products, like medical devices or integrated skincare, drawing from GY's R&D case.

2. Business opportunities: Cross-sector moves, such as Pechoin's R&D company and Shanghai Jahwa's investments, open avenues for component supply or joint R&D projects.

3. Digital and e-commerce insights: Douyin's sales surge (Pechoin's 1692.91% YoY growth) underscores digital channels' importance. Factories can optimize online production and e-commerce supply chains.

4. Case studies: Beauty firms' medical aesthetics expansions, like Yatsen Global's new entity, offer models for exploring new production partnerships.

The article outlines industry trends, client pain points, and solutions for service providers.

1. Industry trends: Medical aesthetics is a new beauty growth driver, with 17% penetration and demand for cyclical solutions, presenting market expansion opportunities.

2. Client pain points: Consumers seek integrated treatment-daily regimens, highlighting a need for consolidated services. Providers can develop medical devices or digital tools.

3. Solutions: Cases like GY's research collaboration and Pechoin's medical aesthetics firm suggest offering R&D partnerships or technical solutions to address gaps.

4. Innovation insights: Cross-sector moves, such as Yatsen Global's research company, encourage focus on biotech applications to enhance service value.

The article discusses platform demands, operational opportunities, and risk mitigation for marketplace optimization.

1. Merchant needs and challenges: Douyin's high-growth potential (Pechoin's 123.68% MoM rise) underscores demand for e-commerce support, requiring platforms to address merchant acquisition and operational efficiency.

2. Platform strategies: Cases suggest attracting beauty brands by leveraging medical aesthetics trends (17% penetration) through targeted recruitment and optimized operations.

3. Risk management: Demand shifts toward integrated regimens necessitate avoiding outdated models, strengthening content moderation, and enhancing user services.

4. Opportunities: Cross-sector moves like Pechoin's create partnership needs; platforms can develop tailored support policies to capture growth.

The article reveals industry shifts, business models, and policy implications for research.

1. Industry trends: Beauty firms' crossover into medical aesthetics, including Pechoin's new company and Marubi's rebranding, signals sector convergence.

2. New business models: Demand shifts from one-off to cyclical-daily solutions drive innovation, such as R&D investments (Shanghai Jahwa's 58% stake) and collaborations (GY case), warranting study of integration strategies.

3. Policy implications: Medical aesthetics' 17% penetration and growth inspire regulatory recommendations for product safety and service standards.

4. Empirical support: Sales data (Pechoin's 1692.91% YoY growth) and demand changes provide a basis for analyzing industry impact.